Advances in Chronic Kidney Disease
Volume 11, Issue 3 , Pages 319-327 , July 2004

The spectrum of cardiovascular disease in children with predialysis chronic kidney disease

  • Blanche M Chavers

      Affiliations

    • Division of Nephrology, Department of Pediatrics, Hennepin County Medical Center; University of Minnesota, Minneapolis, MN, USA
    • Corresponding Author InformationAddress correspondence to Blanche Chavers, MD, University of Minnesota, Department of Pediatrics, Division of Pediatric Nephrology, 420 Delaware Street SE, MMC 491, Minneapolis, MN 55455 USA
    • ,
  • Charles A Herzog

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Hennepin County Medical Center; University of Minnesota, Minneapolis, MN, USA

References 

  1. National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease (Evaluation, classification and stratification). Am J Kidney Dis. 2002;39(suppl 1):S1–S266
  2. Coresh J, Astor BC, Greene T, et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population (Third national health and nutrition examination survey). Am J Kidney Dis. 2003;41:1–12
  3. Culleton BF, Larson MG, Wilson PWF, et al.  Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56:2214–2219
  4. Levin A, Thompson CR, Ethier J, et al.  Left ventricular mass index increase in early renal disease (Impact of decline in hemoglobin). Am J Kidney Dis. 1999;34:125–134
  5. Sarnak MJ, Levey AS, Schoolwerth AC, et al.  Kidney disease as a risk factor for development of cardiovascular disease. Circulation. 2003;108:2154–2169
  6. Foley RN, Parfrey PS, Harnett JD, et al.  Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–192
  7. Levey AS, Beto JA, Coronado BE, et al.  Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853–906
  8. National Kidney Foundation . K/DOQI clinical practice guidelines on managing dyslipiedmias in chronic kidney disease. Am J Kidney Dis. 2003;41(suppl 3):S1–S77
  9. Chavers B, Schnaper HW. Risk factors for cardiovascular disease in children on maintenance dialysis. Adv Ren Replacement Ther. 2001;8:180–190
  10. Grunbaum JA, Kann L, Kinchen SA, et al.  Youth risk behavior surveillance—United States, 2001. J Sch Health. 2002;72:313–328
  11. U.S. Renal Data System. USRDS 2003 Annual Data Report. Available at: http://www.usrds.org/adr.htm. Accessed February 27 2004;
  12. Seikaly MG, Ho PL, Emmett L, et al.  Chronic renal insufficiency in children (The 2001 annual report of the NAPRTCS). Pediatr Nephrol. 2003;18:796–804
  13. Parekh RS, Carroll CE, Wolfe RA, et al.  Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr. 2002;141:191–197
  14. Chavers BM, Li S, Collins AJ, et al.  Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int. 2002;62:648–653
  15. Groothoff JW, Gruppen MP, Offringa M, et al.  Mortality and causes of death of end-stage renal disease in children (A Dutch cohort study). Kidney Int. 2002;61:621–629
  16. Anderson RN, Smith BL. Deaths (Leading Causes for 2001). National Vital Statistics Reports. 2003;52:1–85
  17. Mitsnefes MM, Daniels SR, Schwartz SM, et al.  Changes in left ventricular mass in children and adolescents during chronic dialysis. Pediatr Nephrol. 2001;16:318–323
  18. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334–341
  19. Silberberg JS, Barre PE, Prichard SS, et al.  Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36:286–290
  20. Mitsnefes MM, Kimball TR, Witt SA, et al.  Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. Circulation. 2003;107:864–868
  21. Johnstone LM, Jones CL, Grigg LE, et al.  Left ventricular abnormalities in children, adolescents and young adults with renal disease. Kidney Int. 1996;50:998–1006
  22. Lipshultz SE, Somers MJG, Lipsitz SR, et al.  Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure. Pediatrics. 2003;112:79–86
  23. O’Regan S, Matina D, Ducharme G, et al.  Echocardiographic assessment of cardiac function in children with chronic renal failure. Kidney Int. 1983;24(suppl):S77–S82
  24. Atalay S, Ekim M, Tutar HE, et al.  Systolic and diastolic function in children with chronic renal failure. Pediatr Int. 2002;44:18–23
  25. Ulmer HE, Heupel EW, Scharer K. Long-term evaluation of cardiac function utilizing systolic time intervals in children with chronic renal failure. Int J Pediatr Neprhrol. 1982;3:79–86
  26. Ulmer HE, Greiner H, Schuler HW, et al.  Cardiovascular impairment and physical working capacity in children with chronic renal failure. Acta Paediatr Scand. 1978;67:43–48
  27. Bonzel KE, Wildi B, Weiss M, et al.  Spiroergometric performance of children and adolescents with chronic renal failure. Pediatr Nephrol. 1991;5:22–29
  28. U.S. Renal Data System (USRDS 2002 Annual Data Report). 2002; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
  29. Bosch A, Ulmer HE, Keller HE, et al.  Electrocardiographic monitoring in children with chronic renal failure. Pediatr Nephrol. 1990;4:140–144
  30. Kocak G, Atalay S, Bakkaloglu S, et al.  QT/corrected QT (QTc) intervals and QT/QTc dispersions in children with chronic renal failure. Int J Cardiol. 1999;70:63–67
  31. Suzuki R, Tsumura K, Inoue T, et al.  QT interval prolongation in the patients receiving maintenance hemodialysis. Clin Nephrol. 1998;49:240–244
  32. Jungers P, Massy ZA, Nguyen K, et al.  Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients (A prospective study). Nephrol Dial Transplant. 1997;12:2597–2602
  33. Jungers P, Khao N, Massy ZA, et al.  Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients (A multicentric study in the Ile de France district). Nephrol Dial Transplant. 1999;14:898–902
  34. Zieske AW, Malcom GR, Strong JP. Natural history and risk factors of atherosclerosis in children and youth (The PDAY study). Pediatr Pathol Mol Med. 2002;21:213–237
  35. Strong JP, Malcon GT, Mahan GA, et al.  Prevalence and extent of atherosclerosis in adolescents and young adults (Implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth study). JAMA. 1999;281:727–735
  36. Berenson GS, Srinivasan SR, Bao W, et al.  Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998;338:1650–1656
  37. Nayir A, Bilge I, Kilicaslan I, et al.  Arterial changes in paediatric haemodialysis patients undergoing renal transplantation. Nephrol Dial Transplant. 2001;16:2041–2047
  38. Goodman WG, Goldin J, Kuizon BD, et al.  Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483
  39. Oh J, Wunsch R, Turzer M, et al.  Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation. 2002;106:100–105
  40. Groothoff JW, Gruppen MP, Offringa M, et al.  Increased arterial stiffness in young adults with end-stage renal disease since childhood. J Am Soc Nephrol. 2002;13:2953–2961
  41. Scharer K, Schmidt KG, Soerger M. Cardiac function and structure in patients with chronic renal failure. Pediatr Nephrol. 1999;13:951–965
  42. Locatelli F, Pozzoni P, Tentori F, et al.  Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant. 2003;18(suppl):vii2–vii9
  43. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis. 2003;41(suppl):S11–S17
  44. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000;356:147–152
  45. Cook S, Weitzman M, Auinger P, et al.  Prevalence of a metabolic syndrome phenotype in adolescents (Findings from the third National Health and Nutrition Examination Survey, 1988–1994). Arch Pediatr Adolesc Med. 2003;157:821–827
  46. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascular risk in children. An American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation. 2003;107:1448–1453
  47. Williams CL, Hayman LL, Daniels SR, et al.  Cardiovascular health in childhood. A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2002;106:143–160
  48. Kari JA, Donald AE, Vallance DT, et al.  Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int. 1997;52:468–472
  49. Bennett-Richards KJ, Kattenhorn M, Donald AE, et al.  Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int. 2002;62:1372–1378
  50. Lilien M, Duran M, Van Hoeck K, et al.  Hyperhomocyst (e) inaemia in children with chronic renal failure. Nephrol Dial Transplant. 1999;14:366–368
  51. Merouani ALM, Delvin EE, Genest J, et al.  Plasma homocysteine concentration in children with chronic renal failure. Pediatr Nephrol. 2001;16:805–811
  52. Kang HG, Lee BS, Hahn H, et al.  Reduction of plasma homocysteine by folic acid in children with chronic renal failure. Pediatr Nephrol. 2002;17:511–514
  53. Sebekova K, Podracka L, Heidland A, et al.  Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation—are they inter-related?. Clin Nephrol. 2001;56(suppl):S21–S26
  54. NKF-DOQI Work Group . Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl):S10–S201
  55. National Heart, Lung, and Blood Institute . Update on the 1987 Task Force on High Blood Pressure in Children and Adolescents (A Working Group from the National High Blood Pressure Education Program). Pediatrics. 1996;98:649–658
  56. Mitsnefes M, Ho P-L, McEnery PT. Hypertension and progression of chronic renal insufficiency in children (A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)). J Am Soc Nephrol. 2003;14:2618–2622
  57. Wingen AM, Fabian-Bach C, Schaefer F, et al.  Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children (European study group of nutritional treatment of chronic renal failure in childhood). Lancet. 1997;349:1117–1123
  58. Mitsnefes MM, Kimball TR, Daniels SR. Office and ambulatory blood pressure elevation in children with chronic renal failure. Pediatr Nephrol. 2003;18:145–149
  59. Bartosh SM, Aronson AJ. Childhood hypertension (An update on etiology, diagnosis, and treatment). Pediatr Clin North Am. 1999;46:235–252
  60. Smith PS. Management of end-stage renal disease in children. Ann Pharmacother. 1998;32:929–939
  61. Franscini LMD, Von Vigier RO, Pfister R, et al.  Effectiveness and safety of the angiotensin II antagonist Irbesartan in children with chronic kidney diseases. Am J Hypertens. 2002;15:1057–1063
  62. McGonigle RJ, Wallin JD, Shadduck RK, et al.  Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int. 1984;25:437–444
  63. NKF-DOQI Work Group . IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis. 2001;37(suppl):S182–S238
  64. Chavers BM, Roberts TL, Herzog CA, et al.  Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. Kidney Int. 2004;65:266–273
  65. Warady BA, Ho M. Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol. 2003;18:1055–1062
  66. National Cholesterol Education Program . Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics. 1992;89:525–584
  67. Chavers BM, Hardstedt M, Gillingham KJ. Hyperlipidemia in pediatric kidney transplant recipients treated with cyclosporine. Pediatr Nephrol. 2003;18:565–569
  68. Querfeld U, Lang M, Friedrich B, et al.  Lipoprotein (a) serum levels and apolipoprotein (a) phenotypes in children with chronic renal disease. Pediatr Res. 1993;34:772–776
  69. Querfeld U, Haffner D, Wingen AM, et al.  Treatment with growth hormone increases lipoprotein (a) serum levels in children with chronic renal insufficiency. Eur J Pediatr. 1996;155:913
  70. Berger M, James GP, Davis ER, et al.  Hyperlipidemia in uremic children (Response to peritoneal dialysis and hemodialysis). Clin Nephrol. 1978;9:19–24
  71. Saland JM, Ginsberg H, Fisher EA. Dyslipidemia in pediatric renal disease (Epidemiology, pathophysiology, and management). Curr Opin Pediatr. 2002;14:197–204
  72. Querfeld U. Should hyperlipidemia in children with the nephrotic syndrome be treated?. Pediatr Nephrol. 1999;13:77–84

PII: S1548-5595(04)00071-0

doi: 10.1053/j.arrt.2004.04.002

Advances in Chronic Kidney Disease
Volume 11, Issue 3 , Pages 319-327 , July 2004

Article Tools